Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930710 | 0.85 | MCHR1 (0.45) | MCHR1 | |
| SCHEMBL9963956 | 0.80 | USP30 (0.40) | MCHR1MEN1KMT2ASETD7UCHL1 | |
| SCHEMBL9930853 | 0.79 | DDB1 (0.47) | MCHR1DDB1CRBNHDAC1 | |
| SCHEMBL989533 | 0.77 | DDB1 (0.42) | MCHR1MEN1KMT2ADDB1CRBN | |
| SCHEMBL1004761 | 0.76 | DDB1 (0.40) | DDB1CRBNHDAC1GPR119 | |
| SCHEMBL30339918 | 0.76 | DDB1 (0.40) | DDB1CRBNHDAC1GPR119 | |
| SCHEMBL9968754 | 0.73 | MCHR1 (0.65) | MCHR1GRM2 | |
| SCHEMBL158631 | 0.70 | MCHR1 (0.37) | MCHR1GRM2USP30HDAC1ELANE | |
| SCHEMBL9968776 | 0.70 | BUB1 (0.38) | GRM2DDB1CRBNUCHL1USP30 | |
| SCHEMBL158672 | 0.69 | KAT2B (0.39) | MCHR1GRM2USP30PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993765-B2 | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157460-A1 | TETRAHYDRO-AZACARBOLINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USES THEREOF | MCHR1, MCHR2, MC5R | MCHR1 1/4885GRM2 565/4885MEN1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.